Drugs / Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed
Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed
also known as
Tdcp
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06056050 | Dec 2023 → Apr 2024 overdue | diphtheria, pertussis, tetanus | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed | “Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)” NCT06056050 ↗ |
| Known as | Tdcp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06056050 ↗ |
| Modality | Vaccine | “1 dose of Tdcp vaccine (0.5ml) on Day 0” NCT06056050 ↗ |